Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to modulate targeted immune responses. The company's promising pipeline includes novel antibody therapeutics aimed at treating serious oncological and autoimmune disorders, addressing critical unmet medical needs. With a strong focus on research and development, coupled with strategic partnerships, Surrozen is well-positioned to deliver transformative therapies, offering significant potential for growth and a meaningful impact within the biopharmaceutical landscape.
| Revenue (TTM) | $7.49M |
| Gross Profit (TTM) | $-24.64M |
| EBITDA | $-42.69M |
| Operating Margin | -209.10% |
| Return on Equity | -62.80% |
| Return on Assets | -22.80% |
| Revenue/Share (TTM) | $0.81 |
| Book Value | $-24.21 |
| Price-to-Book | 2.50 |
| Price-to-Sales (TTM) | 35.65 |
| EV/Revenue | 25.25 |
| EV/EBITDA | 0.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 408.60% |
| Shares Outstanding | $11.61M |
| Float | $5.09M |
| % Insiders | 3.18% |
| % Institutions | 101.99% |
Volatility is currently contracting
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the first quarter ended March 31, 2026 and provided a business update.
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of 2,020 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.
